$マーカー・セラピューティクス (MRKR.US)$Reuters· just Marker Therapeutics Awarded $2 Million Grant From Nih in Support of Phase 1 Study Investigating MT-601 in Car-Relapsed Patients With Non-Hodgkin’s Lymphoma
$マーカー・セラピューティクス (MRKR.US)$ Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma Marker Therapeutics (Nasdaq: MRKR) has been awarded a $2 million grant from the NIH Small Business Innovation Research program to support the clinical investigation of MT-601 in patients with non-Hodgkin's lymphoma (NHL) who have relapsed following anti-CD19 CAR T cell therapy. The grant will fund the nation...
を稼ぐことだと言われています
Green Dragon 2024 スレ主 : 2週間と言ってみよう